

# The Aging Gut Motility Decay: May Symbiotics Be Acting as “Implantable” Biologic Pace-Makers?

Y. METUGRIACHUK,<sup>1,2</sup> F. MAROTTA,<sup>3,4</sup> K. PAVASUTHIPAISIT,<sup>5</sup> O. KUROI,<sup>2</sup>  
J. TSUCHIYA,<sup>1,2</sup> A. LORENZETTI,<sup>3</sup> E. FESCE,<sup>3</sup> and E. MINELLI<sup>4</sup>

## ABSTRACT

Motility recording of small and large intestine was performed in old Wistar rats divided into three groups: (a) standard diet, (b) standard diet plus a symbiotic preparation, and (c) standard diet plus a heat-inactivated symbiotic preparation. SCM-III significantly increased the myoelectric activity of small intestine and colon ( $p < 0.01$  versus [a] and [c]) paralleling “young” values of 4-month-old rats and increased the spike burst frequency in the proximal-distal colon ( $p < 0.05$ ). SCM-III significantly increased the frequency and duration of spike bursts in the jejunum, transverse-distal colon, and defecation frequency, while decreasing the intervals of migrating motor complex in the colon ( $p < 0.01$ ) to “young” values with an increased mRNA expression of VIP ( $p < 0.05$ ). Gut flora manipulation aimed to modulate myoelectric activity can tentatively help reversing age-related motility decay.

## INTRODUCTION

**T**HE COLONIC MICROBIOTA mediates many cellular and molecular events in the host that are important to health. It has been shown in recent years how dysbiosis may affect the gut motor and sensory activity.<sup>1,2</sup> Further, physiologic changes in the gastrointestinal tract (including aging) and modifications in diet and host immunity may affect the composition and metabolism of gut microbiota. In clinical practice this is supported by several reports on the onset of irritable bowel syndrome-like symptoms when the gut ecosystem is altered by antibiotic treatments or following gastroenteri-

tis.<sup>3,4</sup> Moreover, besides a number of associated diseases,<sup>5</sup> during aging a relentless derangement of the enteric nervous system occurs,<sup>6</sup> as well as a composition shift of gut flora and its metabolic activities.<sup>7,8</sup> The aim of this study was to probe a possible treatment of aging gut motility disorders from a biologic approach through probiotics.

## MATERIALS AND METHODS

Four bipolar copper electrodes were implanted into the muscular wall of the small intestine of anesthetized rats at 5, 15, 25, and

<sup>1</sup>TMC Hospital, Shizuoka, Japan.

<sup>2</sup>Biokenkyusho Research Laboratory, Shizuoka, Japan.

<sup>3</sup>Hepato-Gastroenterology Unit, SG Hospital, Milan, Italy.

<sup>4</sup>Traditional Medicine and Biotechnology WHO-College Centre, University of Milan, Italy.

<sup>5</sup>Science and Technology Institute, Mahidol, Thailand.

35 cm distal to the duodenojejunal junction. An additional two electrodes were implanted in the proximal and distal colon. The seventh wire was used as ground and implanted in a subcutaneous fold. The abdominal incision was then sutured and the electrodes were tunneled subcutaneously to exit at the interscapular region and the wires connected to a computerized system. After an average postoperative period of 5 days, control recording of basal myoelectric activity (four activity fronts of the MMC propagated over all recording sites during a period of 60 min) were obtained. Afterward, rats were randomly coded and divided into three groups. Group A was given a standard chow diet, group B diet was mixed with the symbiotic preparation, and group C was treated as group B but with a heat-inactivated symbiotic preparation. Four-month-old rats served as the "young" control group.

#### *Motility study procedure*

The experiments were performed in conscious rats and in a fasting state because it has been shown that the intestinal microflora modulates fasting rather than postprandial gut myoelectric activity.<sup>9</sup> The electromyographic recordings were monitored by a polygraph (Sky-Electric-Laboratory, Tokyo, Japan) and motility recordings for each channel were simultaneously analyzed for contractions and relaxations. Subsequently, six consecutive phase IIIs, migrating at least from J5 to J25, were recorded. Phase III was defined as clearly distinguishable periods of regular spiking activity at the maximum frequency and amplitude observed at each electrode, indicated by at least doubling of baseline myoelectric activity.<sup>10</sup> The sensitivity was set to 0.25 mV/cm. The interval between phase IIIs was regarded as the MMC period. The MMC migration ratio was calculated by the ratio between MMC period J5(J25) and MMC period J5 as previously defined.<sup>11</sup> When six consecutive phase IIIs migrating from J5 to J25 were recorded, this ratio was estimated by  $5/(N_{J5} - 1)$ , where  $N_{J5}$  is the total number of phase IIIs at J5 regardless of their aboral migration.

The defecation pattern (frequency, daily fecal weight, fecal mass per each defecation) also was recorded.

#### *Vasoactive intestinal polypeptide analysis: plasma and tissue concentration and gene expression*

Small intestine samples were used to measure the concentration of vasoactive intestinal polypeptide (VIP) by radioimmunoassay (after addition of <sup>125</sup>I-labeled VIP and separation by adding 0.4 mL of activated charcoal, coefficient of variation <8%) and their immunofluorescence was analyzed by a computerized system. Related gene expression was assessed on cryosections by *in situ* hybridization.

#### *Statistical analysis*

Significance was established by analysis of variance and the level of significance was assessed by a Duncan's multiple-range test. Data were expressed in the text as means plus or minus the standard deviation (SD) with a probability value of  $p < 0.05$ .

## RESULTS

The pattern of spike bursts of the small intestine appeared as packets of cyclic MMCs occurring at regular intervals ( $14.3 \pm 4.6$  min) and were propagated from the duodenum to the jejunum at 2 to 3 cm/min<sup>-1</sup> as already described.<sup>12</sup> The overall colonic myoelectrical activity showed a random spike bursts activity at a frequency varying from  $0.4 \pm 0.04$ /min to  $0.6 \pm 0.06$ /min. The analysis showed that old rats had a statistically significant decrease in myoelectric activity when compared with the "young" group ( $p < 0.05$ ). However, no significant change was observed in the defecation pattern. SCM-III exerted an excitatory action on the myoelectric activity of the small intestine and colon as compared with age-matched rats fed a standard diet or the inactivated symbiotic ( $p < 0.01$ ) with values comparable to those recorded in "young" rats. In 37% of treated rats the increased myoelectric activity was not uniform across the different leads and the analysis of intragroup variability showed that this was wider for recordings from leads J5 to J15. Overall, the most intense excitatory effects of SCM-III was recorded at distal jejunal sites (J25 to J35), where it scored up to a 59% increase over baseline. In particular, SCM-III not only

normalized this diminished activity to a "young" level, but also increased it compared with the "young" baseline ( $p < 0.05$ ). The administration of inactivated symbiotics produced only a significant increase of frequency of spike burst in the transverse and distal colon ( $p < 0.05$  versus A). SCM-III was the only treatment causing a significant increase of the frequency and duration of spike bursts in the jejunum, proximal, and distal colon while decreasing the intervals of migrating motor complex in the colon ( $p < 0.01$ ). As compared with group A, baseline B, and "young" rats, SCM-III also increased the frequency of defecation during the daytime (time/hour: 0.65 versus 0.19,  $<0.05$  and caused a trend decrease during nighttime (time/hour: 0.18 versus 0.29,  $p = 0.062$ ).

#### *Vasoactive intestinal polypeptide analysis*

Plasma concentration of VIP was comparable among groups and did not change during symbiotic treatment. Old rats showed a decreased number of VIP-immunoreactive nerve fibers when calculated for a  $100 \mu^2$  tissue area ( $p < 0.01$  versus "young") and a decreased tissue concentration (VIP  $\mu\text{g/g}$ :  $4.4 \pm 1.1$  versus  $6.7 \pm 1.3$ ,  $p < 0.05$ ). SCM-treated rats showed a not significant trend increase of VIP concentration but its quantitative analysis of mRNA showed a significant increase during symbiotic treatment ( $p < 0.05$  versus baseline and versus group C).

## DISCUSSION

Although the pattern and composition of the microflora in healthy people is thought to be fairly stable over the years, it represents a dynamic ecosystem that is subjected to a continuous although vital interplay with dietary live microbes and prebiotics substrates. Indeed, recent studies suggest that aging *per se* affects the intestinal microflora with a decrease in anaerobes and bifidobacteria population and an increase in enterobacteria and in species diversity of the dominant fecal microflora overall.<sup>13</sup> Although it remains to be clarified whether the type of overgrowth flora is an epiphenomenon

of a disease or the overgrowth flora itself may contribute to disease pathophysiology, these changes and the reduced age-related intestinal immunity can be partly reconciled with the increased susceptibility to degenerative or infectious diseases observed in the elderly. Moreover, it has been demonstrated that antibiotics, by altering the gut ecosystem, may bring about a derangement of intestinal motility; this effect may persist even for months afterward. Thus, it is likely that a healthy gut bacterial balance with a net prevalence of the fermenting anaerobic microbiota promoting a regular spike burst activity in small intestine is one of the crucial protecting phenomena mediated by the intestinal microflora.<sup>14</sup> Although the authors did not perform any microbiologic analysis in this study, previous data with same symbiotic had shown its significantly beneficial effect on gut flora composition.<sup>15,16</sup> Finally, although the modulation of gut motility involves multiple pathways with different messengers, hormones, luminal bacterial metabolites, and several other neurotransmitters, the present symbiotic intervention seemed to significantly enhance VIP mRNA expression despite histologic signs of age-related paucity and degeneration of nerve plexus, as described elsewhere.<sup>17-19</sup> Taken altogether, such preliminary data suggest that new effector sites of probiotics in the gut are amenable to more comprehensive age management.<sup>20</sup>

## REFERENCES

1. Justus PG, Fernandez A, Martin JL. Altered myoelectric activity in the experimental blind loop syndrome. *J Clin Invest* 1983;72:1064-1071.
2. Stotzer PO, Bjornsson ES, Abrahamsson H. Interdigestive and postprandial motility in small-intestinal bacterial overgrowth. *Scand J Gastroenterol* 1996;31:875-880.
3. Spiller RC. Postinfectious irritable bowel syndrome. *Gastroenterology* 2003;124:1661-1672.
4. Woodmansey EJ, McMurdo ME, Macfarlane GT, Macfarlane S. Comparison of compositions and metabolic activities of fecal microbiota in young adults and in antibiotic-treated and non-antibiotic-treated elderly subjects. *Appl Environ Microbiol* 2004;70:6113-6122.
5. O'Mahony D, O'Leary P, Quigley EM. Aging and intestinal motility: a review of factors that affect intestinal motility in the aged. *Drugs Aging* 2002;19:515-527.

6. El-Salhy M, Sandstrom O, Holmlund F. Age-induced changes in the enteric nervous system in the mouse. *Mech Aging Dev* 1999;107:93–103.
7. He F, Ouwehand AC, Isolauri E, Hosoda M, Benno Y, Salminen S. Differences in composition and mucosal adhesion of bifidobacteria isolated from healthy adults and healthy seniors. *Curr Microbiol* 2001;43:351–354.
8. Hopkins MJ, Sharp R, Macfarlane GT. Age and disease related changes in intestinal bacterial populations assessed by cell culture, 16S rRNA abundance, and community cellular fatty acid profiles. *Gut* 2001;48:198–205.
9. Abrams GD, Bishop JE. Effect of the normal microbial flora on gastrointestinal motility. *Proc Soc Exp Biol Med* 1967;126:301–304.
10. Husebye E, Hellström PM, Midtvedt T. Introduction of conventional microbial flora to germfree rats increases the frequency of migrating myoelectric complexes. *J Gastrointest Motil* 1992;4:39–45.
11. Husebye E, Hellstrom PM, Sundler F. Influence of microbial species on small intestinal myoelectric activity and transit in germ-free rats. *Am J Physiol Gastrointest Liver Physiol* 2001;280:G368–380.
12. Husebye E, Hellstrom PM, Midwedt T. Intestinal microflora stimulates myoelectric activity of rat small intestine by promoting cyclic initiation and aboral propagation of migrating myoelectric complex. *Dig Dis Sci* 1994;39:946–956.
13. Hebuterne X. Gut changes attributed to aging: effects on intestinal microflora. *Curr Opin Clin Nutr Metab Care* 2003;6:49–54.
14. Husebye E, Hellstrom PM, Midwedt T. Introduction of conventional microbial flora to germ-free rats increases the frequency of migrating myoelectric complexes. *J Gastrointest Mot* 1992;4:39–45.
15. Tsuchiya J, Barreto R, Okura R, Kawakita S, Fesce E, Marotta F. Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. *Chin J Dig Dis* 2004;5:169–174.
16. Lighthouse J, Naito Y, Helmy A, Hotten P, Fuji H, Min CH, Yoshioka M, Marotta F. Endotoxemia and benzodiazepine-like substances in compensated cirrhotic patients: a randomized study comparing the effect of rifaximin alone and in association with a symbiotic preparation. *Hepato Res* 2004;28:155–160.
17. Phillips RJ, Kieffer EJ, Powley TL. Loss of glia and neurons in the myenteric plexus of the aged Fischer 344 rat. *Anat Embryol (Berl)* 2004;209:19–30.
18. El-Salhy M, Sandstrom O. How age changes the content of neuroendocrine peptides in the murine gastrointestinal tract. *Gerontology* 1999;45:17–22.
19. Feher E, Penzes L. Density of substance P, vasoactive intestinal polypeptide and somatostatin-containing nerve fibers in the aging small intestine of the rats. *Gerontology* 1987;33:341–348.
20. Saunier K, Dore J. Gastrointestinal tract and the elderly: functional foods, gut microflora and healthy aging. *Dig Liver Dis* 2002;34(Suppl 2):S19–24.

Address reprint requests to:  
*Prof. F. Marotta, M.D., Ph.D.*  
*Hepato-Gastroenterology Department*  
*San Giuseppe Hospital*  
*via Pisanello, 4*  
*20146 Milano, Italy*

*E-mail: fmarchimede@libero.it*